What Pharma Is Buying From AI Drug Discovery: Inside AstraZeneca’s insitro Deal
Dr. Dereck Mush, MD, MBA
Outer Bio
A discovery platform combining long-lived ex vivo human skin models with machine learning.
What they do
Outer Bio uses its Yuna human-skin platform, automated screening and machine learning to discover skin mechanisms and bioactive compounds.
The record
- Vertical
- Pharma & Drug Discovery
- Sub-segment
- Human skin models and AI discovery
- Product type
- Platform software
- Stage
- Seed
- Headquarters
- Not disclosed
- Region
- North America
- Founded
- Not disclosed
- Total funding
- Undisclosed
Also in Pharma & Drug Discovery
Related on The Signal
Dr. Dereck Mush, MD, MBAThe HealthTech Signal
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Dr. Dereck Mush, MD, MBA
Is AI Drug Discovery Actually Working? What the 2026 Clinical Trial Data Shows
Dr. Dereck Mush, MD, MBA
AI is moving upstream, from molecule design into disease target identification itself
Dr. Dereck Mush, MD, MBA